Navigation Links
Dana-Farber Cancer Institute Chooses MicroStrategy for Clinical Operations and Clinical Research Reporting Applications
Date:1/21/2009

MCLEAN, Va., Jan. 21 /PRNewswire-FirstCall/ -- MicroStrategy(R) Incorporated (Nasdaq: MSTR), a leading worldwide provider of business intelligence (BI) software, today announced that Dana-Farber Cancer Institute has selected the MicroStrategy Business Intelligence Platform(TM) for clinical operations and clinical research reporting applications. Dana-Farber Cancer Institute is a principal teaching affiliate of the Harvard Medical School and is among the leading cancer research and care centers in the United States.

Dana-Farber will use MicroStrategy for its clinical operations reporting application, which will be used by clinic managers, nurses, disease program administrators, and schedulers to improve their ability to manage patient flow through clinical areas, reduce wait times, optimize clinical processes like pharmacy dispenses and medical records management, and monitor staffing levels. Clinical research assistants, statisticians, doctors, and clinical researchers will use the MicroStrategy-based clinical research reporting application for insights into data that will help them write research papers and grants, identify patients for clinical studies, and better understand treatment outcomes.

"We selected MicroStrategy because we needed a fully integrated business intelligence platform that was reliable, scalable, and easy to use," said John Orechia, Clinical and Research Reporting Team Leader of Dana-Farber Cancer Institute. "With MicroStrategy's robust reporting and intuitive Web interface, our personnel will have access to the information they need to make essential decisions for our organization and our patients."

"We are proud to support Dana-Farber Cancer Institute and its multiple reporting applications," said MicroStrategy's COO Sanju Bansal. "Organizations across the healthcare industry rely on MicroStrategy to analyze and improve operations, service quality, and resource utilization."

About Dana-Farber Cancer Institute

Dana-Farber Cancer Institute (www.dana-farber.org) is a principal teaching affiliate of the Harvard Medical School and is among the leading cancer research and care centers in the United States. It is a founding member of the Dana-Farber/Harvard Cancer Center (DF/HCC), designated a comprehensive cancer center by the National Cancer Institute.

About MicroStrategy

Founded in 1989, MicroStrategy is a global leader in business intelligence (BI) technology. MicroStrategy provides integrated reporting, analysis, and monitoring software that helps leading organizations worldwide make better business decisions every day. Companies choose MicroStrategy for its advanced technical capabilities, sophisticated analytics, and superior data and user scalability. More information about MicroStrategy (Nasdaq: MSTR) is available at www.microstrategy.com.

MicroStrategy and MicroStrategy Business Intelligence Platform are either trademarks or registered trademarks of MicroStrategy Incorporated in the United States and certain other countries. Other product and company names mentioned herein may be the trademarks of their respective owners.

    Contact:
    Wende Cover
    MicroStrategy Incorporated
    703-770-1646
    wcover@microstrategy.com


'/>"/>
SOURCE MicroStrategy Incorporated
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Corey McPherson Nash Develops Case Statement for Dana-Farber Cancer Institute Capital Campaign
2. Dana-Farber Cancer Institute Completes Deployment of MedAptus Infusion Services Module
3. Dana-Farber Researcher Named Millennium Pharmaceuticals Career Development Scholar of The Leukemia & Lymphoma Society
4. Conventional prognostic factors fail to explain better prostate cancer survival in most Asian men
5. Survival differences by race most apparent in advanced stages of breast cancer
6. MRI finds breast cancer before it becomes dangerous
7. Investigators uncover intriguing clues to why persistent acid reflux sometimes turns into cancer
8. Pathway links inflammation, angiogenesis and breast cancer
9. Radiologists encouraged to look beyond cancer for clinically unseen diseases
10. Diet high in meat, fat and refined grains linked to risk for colon cancer recurrence, death
11. Immune deficiency linked to a type of eye cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/16/2017)... ... August 16, 2017 , ... Paul Vitenas, MD, FACS , ... Top Doctor. The annual list identifies the nation’s top physicians, in a variety of ... it to the top of Castle Connolly’s coveted ranking. , Castle Connolly is the ...
(Date:8/16/2017)... (PRWEB) , ... August 16, 2017 , ... A global ... has successfully opened clubfoot clinics in all 29 Indian states—bringing the country one step ... in Kangra, Himachal Pradesh, the nonprofit organization is on track to enroll 10,000 children ...
(Date:8/16/2017)... ... August 16, 2017 , ... ... the endoscope after every reprocessing cycle, both between patient procedures and before storage, ... infections. Drying is as important to the prevention of disease transmission and nosocomial ...
(Date:8/16/2017)... ... August 16, 2017 , ... Fusion Flix Inc., a ... programming over four countries and millions of viewers in a partnership with the Amazon ... buy On-Demand and fully available on Blu Ray disc in 2018. Proceeds will be ...
(Date:8/16/2017)... ... August 16, 2017 , ... ... eBook, 9781498499620    ) shares that during the time of a cancer diagnosis, surgery and ... God's love, and all the many ways God shows love to those who ...
Breaking Medicine News(10 mins):
(Date:8/8/2017)...  BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company ... results for the second quarter ended June 30, 2017. ... 2017 and to date: ... the Company,s lead project, BL-8040: Announced ... as novel stem cell mobilization treatment for autologous bone-marrow ...
(Date:8/7/2017)... -- Diplomat Pharmacy, Inc. (NYSE: DPLO), the nation,s largest independent specialty ... 2017.  All comparisons, unless otherwise noted, are to the quarter ... Second Quarter 2017 Highlights include: ... of 3.5% Total prescriptions dispensed of 220,000, ... versus 7.6% Gross profit per prescription ...
(Date:8/2/2017)... Aug. 2, 2017 Fenita J. ... as a Pinnacle Lifetime Professional in the Field ... Manager at Turing Pharmaceuticals, AG. Her skills and ... relationship building.                ... 25 years of experience as a highly successful ...
Breaking Medicine Technology: